NEW BRUNSWICK, N.J., Feb. 18, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to seek treatment solutions for COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2 (also known as 2019-nCoV). This latest collaboration will enhance Janssen's ongoing work with global partners to screen a library of existing antiviral molecules, with the aim of identifying compounds with promising antiviral activity against SARS-CoV-2.
The expanded partnership with BARDA builds on Johnson & Johnson's multipronged response to the COVID-19 outbreak. These efforts, in addition to the ongoing development of a potential vaccine candidate, bring hope of finding a solution against COVID-19 for communities in greatest need in China and around the world.
"We must engage in rigorous research and development in order to identify therapeutic candidates with antiviral activity against the novel coronavirus. Our ambitious goal is to bring forward a solution for patients and ensure future generations do not have to live in fear of the potentially serious consequences of COVID-19," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. "We have a proven track record in partnering with others to develop and deliver antiviral therapies that serve the needs of diverse populations worldwide. While we are at early stages, we are making that commitment again."
To screen potential compounds, Janssen will work with the Rega Institute for Medical Research (KU Leuven), in Belgium. The arrangement couples the Institute's infrastructure, breadth of high throughput screening experience, and capabilities for studying special pathogens with Janssen's drug development resources and antiviral expertise.
Janssen and BARDA will share the research and development costs and mobilize resources to screen a library of antiviral molecules for activity against SARS-CoV-2. The agreement was created under an existing U.S. Government's Other Transaction Authority (OTA), HHSO100201800012C. This is a different agreement from the OTA under which Janssen's SARS-CoV-2 vaccine research is being conducted.
COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19.
For more information on Johnson & Johnson's commitment to combatting COVID-19 visit: www.jnj.com/coronavirus.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.
About the Janssen Pharmaceutical Companies
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal.
Notice to Investors Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding darunavir/cobicistat and development of potential preventive and treatment regimens for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
SOURCE Johnson & Johnson